ROCHE HOLDING LTD S/ADR - RHHBY STOCK NEWS

Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.

Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.

10/23/2023 01:00 AM

News

[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant

Rhea-AI Summary

Roche has entered into an agreement to acquire Telavant Holdings, gaining the rights to develop and commercialize RVT-3101, a novel TL1A directed antibody for the treatment of inflammatory bowel disease and potentially other diseases. Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. The acquisition includes an option to collaborate with Pfizer on a next-generation bispecific antibody.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.78%

Tags

10/19/2023 01:00 AM

News

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products

Rhea-AI Summary

Roche Group reports 1% growth in sales at constant exchange rates in the first nine months of 2023, driven by strong performance in Pharmaceuticals Division. Positive development milestones include EU approval of Evrysdi for babies with spinal muscular atrophy and positive phase III data for Alecensa and Ocrevus.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.24%

Tags

10/18/2023 01:03 AM

News

Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns

Rhea-AI Summary

Roche announces that the Elecsys IL-6 immunoassay has received certification for use in diagnosing neonatal sepsis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.8%

Tags

10/18/2023 01:00 AM

News

Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer

Rhea-AI Summary

Roche announces positive results from Phase III ALINA study in early-stage ALK-positive non-small cell lung cancer

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.8%

Tags

10/13/2023 09:30 AM

News

Late-breaking data for Roche’s BTK inhibitor fenebrutinib show brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis

Rhea-AI Summary

Roche announces positive results from Phase II FENopta study for fenebrutinib in relapsing multiple sclerosis

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.93%

Tags

10/12/2023 01:00 AM

News

New data for Roche’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided

Rhea-AI Summary

Roche announces new data for OCREVUS in multiple sclerosis at ECTRIMS-ACTRIMS Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.08%

Tags

10/11/2023 02:00 AM

News

Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions

Rhea-AI Summary

Roche announces positive late-breaking data on OCREVUS subcutaneous injection for multiple sclerosis treatment

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.63%

Tags

10/11/2023 02:00 AM

News

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity

Rhea-AI Summary

Genentech announces positive results from Phase IV CHIMES trial evaluating Ocrevus in Black and Hispanic/Latinx people with relapsing MS

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.63%

Tags

10/10/2023 01:00 AM

News

Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies

Rhea-AI Summary

Roche announces positive long-term results for Vabysmo in retinal vein occlusion

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.87%

Tags

10/10/2023 01:00 AM

News

Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Rhea-AI Summary

Genentech announces positive long-term results for Vabysmo in macular edema due to retinal vein occlusion

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.87%

Tags

FAQ

What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?

The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.

What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?

The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.

What is Roche Holdings Ltd. S/ADR (RHHBY) known for?

Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.

What is the significance of Columvi® (glofitamab) in Roche's portfolio?

Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does Roche contribute to personalized healthcare?

Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.

What recent innovation has Roche introduced in digital pathology?

Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.

What is Roche's approach to advancing haematology treatments?

Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.